We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
Zhongguo Shi Yan Xue Ye Xue za Zhi 2017 April
Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies. Primary antifungal prophylaxis (PAP) is effective for decreasing incidence of IFD, and the patients will be more tolerable to chemotherapy with less cost and better prognosis. Antifungal drugs as fluconazole, itraconazole, posaconazole, caspofungin and micafungin are all recommended for PAP by many consensus and guidelines. The PAP will be more scientific, appropriate and effective with the development of studies about predicting risk-stratification for IFD, new drugs, pharmacokinetics and integrated prophylaxis. This review summarizes the progress of PAP in hematological malignancy patients in recent years.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app